5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson’s disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The dual-hit hypothesis of Parkinson’s disease (PD) originally postulated that a neurotropic pathogen leads to formation of α-synuclein pathology in the olfactory bulb (OB) and dorsal motor nucleus of the vagus (DMV) and then invades the brain from these two entry points. Little work has been conducted to validate an important underlying premise for the dual-hit hypothesis, namely that the initial Lewy pathology does arise simultaneously in the OB and the enteric nervous system (ENS) plexuses and DMV at the earliest disease stage. We conducted a focused re-analysis of two postmortem datasets, which included large numbers of mild Lewy body disease (LBD) cases. We found that cases with α-synuclein pathology restricted to the peripheral autonomic nervous system and/or lower brainstem (early body-first LBD cases) very rarely had any OB pathology, suggesting that Lewy pathology commonly arises in the ENS without concomitant involvement of the OB. In contrast, cases with mild amygdala-predominant Lewy pathology (early brain-first LBD cases) nearly always showed OB pathology. This is compatible with the first pathology being triggered in the OB or amygdala followed by secondary spreading to connected structures, but without early involvement of the ENS or lower brainstem. These observations support that the pathologic process starts in either the olfactory bulb or the ENS, but rarely in the olfactory bulb and gut simultaneously. More studies on neuropathological datasets are warranted to reproduce these findings. The agreement between the revised single-hit hypothesis and the recently proposed brain-first vs. body-first model of LBD is discussed.

          Related collections

          Most cited references71

          • Record: found
          • Abstract: found
          • Article: not found

          Neuropathological stageing of Alzheimer-related changes

          Eighty-three brains obtained at autopsy from nondemented and demented individuals were examined for extracellular amyloid deposits and intraneuronal neurofibrillary changes. The distribution pattern and packing density of amyloid deposits turned out to be of limited significance for differentiation of neuropathological stages. Neurofibrillary changes occurred in the form of neuritic plaques, neurofibrillary tangles and neuropil threads. The distribution of neuritic plaques varied widely not only within architectonic units but also from one individual to another. Neurofibrillary tangles and neuropil threads, in contrast, exhibited a characteristic distribution pattern permitting the differentiation of six stages. The first two stages were characterized by an either mild or severe alteration of the transentorhinal layer Pre-alpha (transentorhinal stages I-II). The two forms of limbic stages (stages III-IV) were marked by a conspicuous affection of layer Pre-alpha in both transentorhinal region and proper entorhinal cortex. In addition, there was mild involvement of the first Ammon's horn sector. The hallmark of the two isocortical stages (stages V-VI) was the destruction of virtually all isocortical association areas. The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Staging of brain pathology related to sporadic Parkinson’s disease

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

              The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them. REM sleep behavior disorder, severe neuroleptic sensitivity, and reduced striatal dopamine transporter activity on functional neuroimaging are given greater diagnostic weighting as features suggestive of a DLB diagnosis. The 1-year rule distinguishing between DLB and Parkinson disease with dementia may be difficult to apply in clinical settings and in such cases the term most appropriate to each individual patient should be used. Generic terms such as Lewy body (LB) disease are often helpful. The authors propose a new scheme for the pathologic assessment of LBs and Lewy neurites (LN) using alpha-synuclein immunohistochemistry and semiquantitative grading of lesion density, with the pattern of regional involvement being more important than total LB count. The new criteria take into account both Lewy-related and Alzheimer disease (AD)-type pathology to allocate a probability that these are associated with the clinical DLB syndrome. Finally, the authors suggest patient management guidelines including the need for accurate diagnosis, a target symptom approach, and use of appropriate outcome measures. There is limited evidence about specific interventions but available data suggest only a partial response of motor symptoms to levodopa: severe sensitivity to typical and atypical antipsychotics in approximately 50%, and improvements in attention, visual hallucinations, and sleep disorders with cholinesterase inhibitors.
                Bookmark

                Author and article information

                Contributors
                borghammer@clin.au.dk
                Journal
                NPJ Parkinsons Dis
                NPJ Parkinsons Dis
                NPJ Parkinson's Disease
                Nature Publishing Group UK (London )
                2373-8057
                30 November 2022
                30 November 2022
                2022
                : 8
                : 166
                Affiliations
                [1 ]GRID grid.154185.c, ISNI 0000 0004 0512 597X, Department of Nuclear Medicine and PET, , Aarhus University Hospital, ; Aarhus, Denmark
                [2 ]GRID grid.7048.b, ISNI 0000 0001 1956 2722, Department of Clinical Medicine, , Aarhus University, ; Aarhus, Denmark
                [3 ]GRID grid.7737.4, ISNI 0000 0004 0410 2071, Department of Pathology, , University of Helsinki, and HUS Diagnostic Center, University Hospital, ; Helsinki, Finland
                [4 ]GRID grid.136593.b, ISNI 0000 0004 0373 3971, Brain Bank for Neurodevelopmental, Neurological and Psychiatric Disorders, United Graduate School of Child Development, , Osaka University, ; Osaka, Japan
                [5 ]GRID grid.417092.9, Brain Bank for Aging Research, , Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, ; Tokyo, Japan
                Author information
                http://orcid.org/0000-0001-6391-8052
                http://orcid.org/0000-0003-2823-8785
                http://orcid.org/0000-0001-7399-9749
                Article
                436
                10.1038/s41531-022-00436-2
                9712280
                36450732
                863278b0-32a7-474c-8f23-c13a6a7d38ef
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 3 September 2022
                : 17 November 2022
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100003554, Lundbeckfonden (Lundbeck Foundation);
                Funded by: JSPS 22K00570 AMED JP21wm0425019 JSPS JP22H04923 (CoBiA)
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                parkinson's disease,neuroscience
                parkinson's disease, neuroscience

                Comments

                Comment on this article